The Future of Esophageal Cancer Care: Tailoring Surgery and Chemoradiation with Precision Tools
The CROSS regimen led to a substantial improvement in overall survival, nearly doubling the median survival time.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Esophageal Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- Clinical Trials Update in Resectable Esophageal Cancer
- Advances in targeted therapy for esophageal cancer
- A review of esophageal cancer research: emerging trends, progress and perspectives
- An esophageal cancer clinical trial - ES3